Share this article
Share this article
PLYMOUTH MEETING, Pa., May 17, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the appointment of Roger D. Dansey, M.D. to its Board of Directors. The appointment adds extensive expertise in drug development to the INOVIO Board as the company strengthens its focus on its late stage product development programs. Currently the Chief Medical Officer at Seagen (formerly Seattle Genetics), Dr. Dansey has played a central role in Seagen s efforts to become a globally recognized, multi product oncology company.
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from.
Gene Editing Expands to New Types of Immune Cells
Gladstone researchers fine-tuned CRISPR-Cas9 genome editing to work on human immune cells called monocytes
News provided by
Share this article
Share this article
SAN FRANCISCO, May 11, 2021 /PRNewswire/ In the decade since the advent of CRISPR-Cas9 gene editing, researchers have used the technology to delete or change genes in a growing number of cell types. Now, researchers at Gladstone Institutes and UC San Francisco (UCSF) have added human monocytes white blood cells that play key roles in the immune system to that list.
A team of scientists at Gladstone Institutes and UC San Francisco led by Alex Marson (left) and Nevan Krogan (right) fine-tuned CRISPR-Cas9 genome editing to help understand how the human immune system fights viruses and microbes.